Log in

Relevant bibliographies by topics / New class discovery / Journal articles

Journal articles on the topic 'New class discovery'

To see the other types of publications on this topic, follow the link: New class discovery.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'New class discovery.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Golub, T. R., D. K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, J. P. Mesirov, H. Coller, et al. "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring." Science 286, no. 5439 (October 15, 1999): 531–37. http://dx.doi.org/10.1126/science.286.5439.531.

Full text

Abstract:

Although cancer classification has improved over the past 30 years, there has been no general approach for identifying new cancer classes (class discovery) or for assigning tumors to known classes (class prediction). Here, a generic approach to cancer classification based on gene expression monitoring by DNA microarrays is described and applied to human acute leukemias as a test case. A class discovery procedure automatically discovered the distinction between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) without previous knowledge of these classes. An automatically derived class predictor was able to determine the class of new leukemia cases. The results demonstrate the feasibility of cancer classification based solely on gene expression monitoring and suggest a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge.

APA, Harvard, Vancouver, ISO, and other styles

2

Fukunaga, Alex S. "Automated Discovery of Local Search Heuristics for Satisfiability Testing." Evolutionary Computation 16, no. 1 (March 2008): 31–61. http://dx.doi.org/10.1162/evco.2008.16.1.31.

Full text

Abstract:

The development of successful metaheuristic algorithms such as local search for a difficult problem such as satisfiability testing (SAT) is a challenging task. We investigate an evolutionary approach to automating the discovery of new local search heuristics for SAT. We show that several well-known SAT local search algorithms such as Walksat and Novelty are composite heuristics that are derived from novel combinations of a set of building blocks. Based on this observation, we developed CLASS, a genetic programming system that uses a simple composition operator to automatically discover SAT local search heuristics. New heuristics discovered by CLASS are shown to be competitive with the best Walksat variants, including Novelty+. Evolutionary algorithms have previously been applied to directly evolve a solution for a particular SAT instance. We show that the heuristics discovered by CLASS are also competitive with these previous, direct evolutionary approaches for SAT. We also analyze the local search behavior of the learned heuristics using the depth, mobility, and coverage metrics proposed by Schuurmans and Southey.

APA, Harvard, Vancouver, ISO, and other styles

3

Dumas, Jacques, Robert Sibley, Bernd Riedl, Mary Katherine Monahan, Wendy Lee, Timothy B. Lowinger, Anikó M. Redman, et al. "Discovery of a new class of p38 kinase inhibitors." Bioorganic & Medicinal Chemistry Letters 10, no. 18 (September 2000): 2047–50. http://dx.doi.org/10.1016/s0960-894x(00)00270-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

BOND, S., A. DRAFFAN, J. LAMBERT, C. LIM, B. LIN, A. LUTTICK, J. MITCHELL, C. MORTON, R. NEARN, and V. SANFORD. "Discovery of a New Class of Polycyclic RSV Inhibitors." Antiviral Research 74, no. 3 (June 2007): A30. http://dx.doi.org/10.1016/j.antiviral.2007.01.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Koltun, Elena, Steven Richards, Vicky Chan, Jason Nachtigall, Hongwang Du, Kevin Noson, Adam Galan, et al. "Discovery of a new class of glucosylceramide synthase inhibitors." Bioorganic & Medicinal Chemistry Letters 21, no. 22 (November 2011): 6773–77. http://dx.doi.org/10.1016/j.bmcl.2011.09.037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mihalic, Jeffrey T., Yong-Jae Kim, Mike Lizarzaburu, Xiaoqi Chen, Jeff Deignan, Malgorzata Wanska, Ming Yu, et al. "Discovery of a new class of ghrelin receptor antagonists." Bioorganic & Medicinal Chemistry Letters 22, no. 5 (March 2012): 2046–51. http://dx.doi.org/10.1016/j.bmcl.2012.01.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bortolato, Andrea, Andrew S. Doré, Kaspar Hollenstein, Benjamin G. Tehan, Jonathan S. Mason, and Fiona H. Marshall. "Structure of Class B GPCRs: new horizons for drug discovery." British Journal of Pharmacology 171, no. 13 (June 10, 2014): 3132–45. http://dx.doi.org/10.1111/bph.12689.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stout, T. J., M. P. Costi, D. Barlocco, M. Rinaldi, B. Shoichet, K. M. Perry, I. D. Kuntz, and R. M. Stroud. "Structure-based discovery of a new class of enzyme inhibitors." Acta Crystallographica Section A Foundations of Crystallography 52, a1 (August 8, 1996): C207. http://dx.doi.org/10.1107/s0108767396091064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Pancotti, A., S. Parapini, M. Dell'Agli, L. Gambini, C. Galli, E. Sangiovanni, N. Basilico, E. Bosisio, D. Taramelli, and S. Romeo. "Discovery of oxybisbenzoylamides as a new class of antimalarial agents." MedChemComm 6, no. 6 (2015): 1173–77. http://dx.doi.org/10.1039/c5md00115c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chung, Chun-wa, and David F. Tough. "Bromodomains: a new target class for small molecule drug discovery." Drug Discovery Today: Therapeutic Strategies 9, no. 2-3 (September 2012): e111-e120. http://dx.doi.org/10.1016/j.ddstr.2011.12.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Barril, Xavier, Paul Brough, Martin Drysdale, Roderick E. Hubbard, Andrew Massey, Allan Surgenor, and Lisa Wright. "Structure-based discovery of a new class of Hsp90 inhibitors." Bioorganic & Medicinal Chemistry Letters 15, no. 23 (December 2005): 5187–91. http://dx.doi.org/10.1016/j.bmcl.2005.08.092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Willis, Mary, Matthias Götz, Anil K. Kandalam, Gerd F. Ganteför, and Puru Jena. "Hyperhalogens: Discovery of a New Class of Highly Electronegative Species." Angewandte Chemie International Edition 49, no. 47 (October 6, 2010): 8966–70. http://dx.doi.org/10.1002/anie.201002212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hollister, Leo E. "New class of hallucinogens: GABA-enhancing agents." Drug Development Research 21, no. 3 (1990): 253–56. http://dx.doi.org/10.1002/ddr.430210311.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Dandliker, Peter J., Steve D. Pratt, Angela M. Nilius, Candace Black-Schaefer, Xiaoan Ruan, Danli L. Towne, Richard F. Clark, et al. "Novel Antibacterial Class." Antimicrobial Agents and Chemotherapy 47, no. 12 (December 2003): 3831–39. http://dx.doi.org/10.1128/aac.47.12.3831-3839.2003.

Full text

Abstract:

ABSTRACT We report the discovery and characterization of a novel ribosome inhibitor (NRI) class that exhibits selective and broad-spectrum antibacterial activity. Compounds in this class inhibit growth of many gram-positive and gram-negative bacteria, including the common respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis, and are nontoxic to human cell lines. The first NRI was discovered in a high-throughput screen designed to identify inhibitors of cell-free translation in extracts from S. pneumoniae. The chemical structure of the NRI class is related to antibacterial quinolones, but, interestingly, the differences in structure are sufficient to completely alter the biochemical and intracellular mechanisms of action. Expression array studies and analysis of NRI-resistant mutants confirm this difference in intracellular mechanism and provide evidence that the NRIs inhibit bacterial protein synthesis by inhibiting ribosomes. Furthermore, compounds in the NRI series appear to inhibit bacterial ribosomes by a new mechanism, because NRI-resistant strains are not cross-resistant to other ribosome inhibitors, such as macrolides, chloramphenicol, tetracycline, aminoglycosides, or oxazolidinones. The NRIs are a promising new antibacterial class with activity against all major drug-resistant respiratory pathogens.

APA, Harvard, Vancouver, ISO, and other styles

15

Schwarzacher, Walter. "Metal Nanostructures: A New Class of Electronic Devices." Electrochemical Society Interface 8, no. 1 (March 1, 1999): 20–24. http://dx.doi.org/10.1149/2.f04991if.

Full text

Abstract:

Since the discovery of the transistor just over 50 years ago (see Interface Vol. 6, No. 1), the cost of electronic systems has been reduced and their performance dramatically improved. New technology has resulted in individual components becoming ever smaller and more highly integrated. Controlling the structure of semiconductor devices on a submicron scale has become routine.

APA, Harvard, Vancouver, ISO, and other styles

16

Blanco, Delia, Esther Perez-Herran, Mónica Cacho, Lluís Ballell, Julia Castro, Rubén González del Río, José Luis Lavandera, et al. "Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs." Antimicrobial Agents and Chemotherapy 59, no. 4 (January 12, 2015): 1868–75. http://dx.doi.org/10.1128/aac.03913-14.

Full text

Abstract:

ABSTRACTOne way to speed up the TB drug discovery process is to search for antitubercular activity among compound series that already possess some of the key properties needed in anti-infective drug discovery, such as whole-cell activity and oral absorption. Here, we present MGIs, a new series ofMycobacterium tuberculosisgyrase inhibitors, which stem from the long-term efforts GSK has dedicated to the discovery and development of novel bacterial topoisomerase inhibitors (NBTIs). The compounds identified were found to be devoid of fluoroquinolone (FQ) cross-resistance and seem to operate through a mechanism similar to that of the previously described NBTI GSK antibacterial drug candidate. The remarkablein vitroandin vivoantitubercular profiles showed by the hits has prompted us to further advance the MGI project to full lead optimization.

APA, Harvard, Vancouver, ISO, and other styles

17

Guenard, Daniel, Francoise Gueritte-Voegelein, and Francois Lavelle. "Taxoids: A New Class of Antimitotic Compounds." Current Pharmaceutical Design 1, no. 1 (June 1995): 95–112. http://dx.doi.org/10.2174/1381612801666220524192845.

Full text

Abstract:

Paclitaxel (Taxol®) and docetaxel (Taxotere®) are the first representatives of taxoids , a new class of antitumor compounds. These two taxoids are clinically active against breast, ovarian and lung cancers. Taxoids are highly complex diterpenoids from natural origin. Preclinical and clinical develop-ments have been made possible after a long and sustained chemical effort : paclitaxel is extracted from the barks of the Pacific yew tree Taxus brevifolia whereas docetaxel is prepared by hemisynthesis starting from 10-deacetyl-baccatin ill, a non cytotoxic precursor found in the needles of the European yew tree Taxus baccata . These two drugs are active in various in vitro and in vivo preclinical models (cell lines, cloning of human tumor stem cells, murine grafted tumors , human xenografts). Taxoids constitute anew class of antimitotic agents different from vinca-alkaloids: on the one hand, paclitaxel and docetaxel can be considered as inhibitors of the reaction of depolymerization of microtubules into tubulin ; on the other hand, vinca-a!kaloids inhibit the reaction of polymerization of tubulin into microtubules. An active program of medicinal chemistry is done in various pharmaceutical and academic Institutions with two objectives: knowledge of structure-activity relationships and selection of new candidates for clinical trials. With the taxoid series, a variety of analogs have been prepared for their antitubulin and biological properties . Concerning the tubulin binding, some important structure activity relationships have been proposed. In this review the contribution of each functional group of docetaxel will be discussed following the evolution of antitubulin activity, going from docetaxel to taxoids possessing the minimum requirement of recognition by tubulin . The conformation of docetaxel and analogs will be compared taking into account the contribution and relevance of X-rays, NMR and molecular modelling studies in determining the molecular shape of active and inactive compounds.

APA, Harvard, Vancouver, ISO, and other styles

18

Goff, Aaron, Daire Cantillon, Leticia Muraro Wildner, and Simon J. Waddell. "Multi-Omics Technologies Applied to Tuberculosis Drug Discovery." Applied Sciences 10, no. 13 (July 3, 2020): 4629. http://dx.doi.org/10.3390/app10134629.

Full text

Abstract:

Multi-omics strategies are indispensable tools in the search for new anti-tuberculosis drugs. Omics methodologies, where the ensemble of a class of biological molecules are measured and evaluated together, enable drug discovery programs to answer two fundamental questions. Firstly, in a discovery biology approach, to find new targets in druggable pathways for target-based investigation, advancing from target to lead compound. Secondly, in a discovery chemistry approach, to identify the mode of action of lead compounds derived from high-throughput screens, progressing from compound to target. The advantage of multi-omics methodologies in both of these settings is that omics approaches are unsupervised and unbiased to a priori hypotheses, making omics useful tools to confirm drug action, reveal new insights into compound activity, and discover new avenues for inquiry. This review summarizes the application of Mycobacterium tuberculosis omics technologies to the early stages of tuberculosis antimicrobial drug discovery.

APA, Harvard, Vancouver, ISO, and other styles

19

Han, Mei-Ling, Yu Shen, Ying Leng, Hua Zhang, and Jian-Min Yue. "New rearranged limonoids from Walsura cochinchinensis." RSC Adv. 4, no. 37 (2014): 19150–58. http://dx.doi.org/10.1039/c4ra00708e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Prasit, P., M. Belley, C. Brideau, C. Chan, S. Charleson, J. F. Evans, R. Fortin, et al. "A new class of leukotriene biosynthesis inhibitors: The discovery of MK0591." Bioorganic & Medicinal Chemistry Letters 2, no. 11 (November 1992): 1395–98. http://dx.doi.org/10.1016/s0960-894x(00)80520-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bharate, Sandip B., Atish Rodge, Rajendra K. Joshi, Jaspreet Kaur, Shaila Srinivasan, S. Senthil Kumar, Asha Kulkarni-Almeida, Sarala Balachandran, Arun Balakrishnan, and Ram A. Vishwakarma. "Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists." Bioorganic & Medicinal Chemistry Letters 18, no. 24 (December 2008): 6357–61. http://dx.doi.org/10.1016/j.bmcl.2008.10.085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Rega, Michele F., Marilisa Leone, Dawoon Jung, Naomi J. H. Cotton, John L. Stebbins, and Maurizio Pellecchia. "Structure-based discovery of a new class of Bcl-xL antagonists." Bioorganic Chemistry 35, no. 4 (August 2007): 344–53. http://dx.doi.org/10.1016/j.bioorg.2007.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Savan, Ram, Azumi Aman, Kenji Sato, Ryoji Yamaguchi, and Masahiro Sakai. "Discovery of a new class of immunoglobulin heavy chain from fugu." European Journal of Immunology 35, no. 11 (November 2005): 3320–31. http://dx.doi.org/10.1002/eji.200535248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Dausse, Eric, Sonia Da Rocha Gomes, and Jean-Jacques Toulmé. "Aptamers: a new class of oligonucleotides in the drug discovery pipeline?" Current Opinion in Pharmacology 9, no. 5 (October 2009): 602–7. http://dx.doi.org/10.1016/j.coph.2009.07.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

ALVARADO, S. I., A. D. CREWS, P. J. WEPPLO, R. F. DOEHNER, T. E. BRADY, D. M. GANGE, and D. L. LITTLE. "ChemInform Abstract: Discovery of a New Class of Herbicides: Sulfonyl Carboxamides." ChemInform 24, no. 43 (August 20, 2010): no. http://dx.doi.org/10.1002/chin.199343323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Graham, Thomas H., Wensheng Liu, Andreas Verras, Iyassu K. Sebhat, Yusheng Xiong, Kelly Bleasby, Urmi R. Bhatt, et al. "A new class of prolylcarboxypeptidase inhibitors, Part 1: Discovery and evaluation." Bioorganic & Medicinal Chemistry Letters 22, no. 8 (April 2012): 2811–17. http://dx.doi.org/10.1016/j.bmcl.2012.02.075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sokolova, Anastasiya S., Olga I. Yarovaya, Andrey V. Shernyukov, Yuriy V. Gatilov, Yuliya V. Razumova, Vladimir V. Zarubaev, Tatiana S. Tretiak, Andrey G. Pokrovsky, Oleg I. Kiselev, and Nariman F. Salakhutdinov. "Discovery of a new class of antiviral compounds: Camphor imine derivatives." European Journal of Medicinal Chemistry 105 (November 2015): 263–73. http://dx.doi.org/10.1016/j.ejmech.2015.10.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Richards, Steven, and et al et al. "ChemInform Abstract: Discovery of a New Class of Glucosylceramide Synthase Inhibitors." ChemInform 43, no. 11 (February 16, 2012): no. http://dx.doi.org/10.1002/chin.201211126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bellamy, Francois D., Jean B. Chazan, Pierre Dodey, Patrick Dutartre, Khan Ou, Marc Pascal, and Jacques Robin. "(Benzoylphenyl)piperidines: a new class of immunomodulators." Journal of Medicinal Chemistry 34, no. 5 (May 1991): 1545–52. http://dx.doi.org/10.1021/jm00109a004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Edwards, Michael L., David M. Stemerick, and Prasad S. Sunkara. "Chalcones: a new class of antimitotic agents." Journal of Medicinal Chemistry 33, no. 7 (July 1990): 1948–54. http://dx.doi.org/10.1021/jm00169a021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Jain, Jainendra, Y. Kumar, Reema Sinha, Rajeev Kumar, and James Stables. "Menthone Aryl Acid Hydrazones: A New Class of Anticonvulsants." Medicinal Chemistry 7, no. 1 (January 1, 2011): 56–61. http://dx.doi.org/10.2174/157340611794072689.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Gallinari, Paola, Gessica Filocamo, Philip Jones, Simonetta Pazzaglia, and Christian Steinkühler. "Smoothened antagonists: a promising new class of antitumor agents." Expert Opinion on Drug Discovery 4, no. 5 (May 2009): 525–44. http://dx.doi.org/10.1517/17460440902852686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Lenkeit, Felina, Iris Eckert, Jörg S. Hartig, and Zasha Weinberg. "Discovery and characterization of a fourth class of guanidine riboswitches." Nucleic Acids Research 48, no. 22 (November 25, 2020): 12889–99. http://dx.doi.org/10.1093/nar/gkaa1102.

Full text

Abstract:

Abstract Riboswitches are RNAs that specifically sense a small molecule and regulate genes accordingly. The recent discovery of guanidine-binding riboswitches revealed the biological significance of this compound, and uncovered genes related to its biology. For example, certain sugE genes encode guanidine exporters and are activated by the riboswitches to reduce toxic levels of guanidine in the cell. In order to study guanidine biology and riboswitches, we applied a bioinformatics strategy for discovering additional guanidine riboswitches by searching for new candidate motifs associated with sugE genes. Based on in vitro and in vivo experiments, we determined that one of our six best candidates is a new structural class of guanidine riboswitches. The expression of a genetic reporter was induced 80-fold in response to addition of 5 mM guanidine in Staphylococcus aureus. This new class, called the guanidine-IV riboswitch, reveals additional guanidine-associated protein domains that are extremely rarely or never associated with previously established guanidine riboswitches. Among these protein domains are two transporter families that are structurally distinct from SugE, and could represent novel types of guanidine exporters. These results establish a new metabolite-binding RNA, further validate a bioinformatics method for finding riboswitches and suggest substrate specificities for as-yet uncharacterized transporter proteins.

APA, Harvard, Vancouver, ISO, and other styles

34

Gootz, T. D. "Discovery and development of new antimicrobial agents." Clinical Microbiology Reviews 3, no. 1 (January 1990): 13–31. http://dx.doi.org/10.1128/cmr.3.1.13.

Full text

Abstract:

The unprecedented growth in the number of new antibiotics over the past two decades has been the result of extensive research efforts that have exploited the growing body of knowledge describing the interactions of antibiotics with their targets in bacterial cells. Information gained from one class of antimicrobial agents has often been used to advance the development of other classes. In the case of beta-lactams, information on structure-activity relationships gleaned from penicillins and cephalosporins was rapidly applied to the cephamycins, monobactams, penems, and carbapenems in order to discover broad-spectrum agents with markedly improved potency. These efforts have led to the introduction of many new antibiotics that demonstrate outstanding clinical efficacy and improved pharmacokinetics in humans. The current review discusses those factors that have influenced the rapid proliferation of new antimicrobial agents, including the discovery of new lead structures from natural products and the impact of bacterial resistance development in the clinical setting. The development process for a new antibiotic is discussed in detail, from the stage of early safety testing in animals through phase I, II, and III clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

35

Yamaguchi, Shinjiro. "Discovery of strigolactones as a new hormone class that inhibits shoot branching." Journal of Pesticide Science 34, no. 4 (2009): 310–14. http://dx.doi.org/10.1584/jpestics.34.310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Badolato, Mariateresa, Fabrizio Manetti, Antonio Garofalo, and Francesca Aiello. "Triazolopyrimidinium salts: discovery of a new class of agents for cancer therapy." Future Medicinal Chemistry 12, no. 5 (March 2020): 387–402. http://dx.doi.org/10.4155/fmc-2019-0317.

Full text

Abstract:

Aim: The [1,2,4]triazolo[1,5- a]pyrimidine core is highly privileged in medicinal chemistry due to its versatile pharmacological activity profile. Recently, the search for novel anticancer agents has focused on [1,2,4]triazolo[1,5- a]pyrimidine derivatives. Results: Our hit functionalization has led to the discovery of new [1,2,4]triazolo[1,5- a]pyrimidinium salts with potential anticancer activity. Among a small library of molecules, compound 9 significantly inhibits cancer cell growth in a panel of in vitro models. Molecular docking studies and preliminary binding assay have displayed that 9 could directly bind the Src homology 2 (SH2) domain of STAT3 protein. Conclusion: Compound 9 is a novel promising lead compound that motivates additional evaluation of [1,2,4]triazolo[1,5- a]pyrimidinium salts as novel potential chemotherapeutics.

APA, Harvard, Vancouver, ISO, and other styles

37

Chen, Xi, Simon P. Ellingsen, Zhi-Yuan Ren, Andrej M. Sobolev, Sergey Parfenov, and Zhi-Qiang Shen. "Discovery of a New Class I Methanol Maser Transition at 266.8 GHz." Astrophysical Journal 877, no. 2 (May 29, 2019): 90. http://dx.doi.org/10.3847/1538-4357/ab1078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Voronkov, M. A., A. J. Walsh, J. L. Caswell, S. P. Ellingsen, S. L. Breen, S. N. Longmore, C. R. Purcell, and J. S. Urquhart. "Discovery of the new class I methanol maser transition at 23.4 GHz." Monthly Notices of the Royal Astronomical Society 413, no. 4 (March 2, 2011): 2339–44. http://dx.doi.org/10.1111/j.1365-2966.2011.18297.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Smith, Roger A., Ajay Bhargava, Christopher Browe, Jinshan Chen, Jacques Dumas, Holia Hatoum-Mokdad, and Romulo Romero. "Discovery and parallel synthesis of a new class of cathepsin k inhibitors." Bioorganic & Medicinal Chemistry Letters 11, no. 22 (November 2001): 2951–54. http://dx.doi.org/10.1016/s0960-894x(01)00600-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ducray, Pierre, Noëlle Gauvry, François Pautrat, Thomas Goebel, Joerg Fruechtel, Yves Desaules, Sandra Schorderet Weber, et al. "Discovery of amino-acetonitrile derivatives, a new class of synthetic anthelmintic compounds." Bioorganic & Medicinal Chemistry Letters 18, no. 9 (May 2008): 2935–38. http://dx.doi.org/10.1016/j.bmcl.2008.03.071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Monastyrskyi, Andrii, Simon Bayle, Victor Quereda, Wayne Grant, Michael Cameron, Derek Duckett, and William Roush. "Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors." Bioorganic & Medicinal Chemistry Letters 28, no. 3 (February 2018): 400–404. http://dx.doi.org/10.1016/j.bmcl.2017.12.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Imaeda, Yasuhiro, Toshio Miyawaki, Hiroki Sakamoto, Fumio Itoh, Noriko Konishi, Katsuhiko Hiroe, Masaki Kawamura, Toshimasa Tanaka, and Keiji Kubo. "Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors." Bioorganic & Medicinal Chemistry 16, no. 5 (March 2008): 2243–60. http://dx.doi.org/10.1016/j.bmc.2007.11.073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Wu, Zhicai, Cangming Yang, Yusheng Xiong, Zhe Feng, Matthew Lombardo, Andreas Verras, Renee M. Chabin, et al. "Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine." Bioorganic & Medicinal Chemistry Letters 22, no. 4 (February 2012): 1774–78. http://dx.doi.org/10.1016/j.bmcl.2011.12.064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

De Souza, Marcus. "New Fluoroquinolones: A Class of Potent Antibiotics." Mini-Reviews in Medicinal Chemistry 5, no. 11 (November 1, 2005): 1009–17. http://dx.doi.org/10.2174/138955705774575246.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Jarvis, Bruce B., Yin-Won Lee, F. Taha Cömezoḡlu, S. Nilgün Cömezoḡlu, and George A. Bean. "Myrotoxins: a new class of macrocyclic trichothecenes." Tetrahedron Letters 26, no. 40 (January 1985): 4859–62. http://dx.doi.org/10.1016/s0040-4039(00)94970-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Harrison, Charlotte. "New switch to activate class B GPCRs." Nature Reviews Drug Discovery 6, no. 3 (March 2007): 185. http://dx.doi.org/10.1038/nrd2274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gilmour, Raymond, J. Estelle Foster, Qin Sheng, Jonathan R. McClain, Anna Riley, Pei-Ming Sun, Wai-Leung Ng, et al. "New Class of Competitive Inhibitor of Bacterial Histidine Kinases." Journal of Bacteriology 187, no. 23 (December 1, 2005): 8196–200. http://dx.doi.org/10.1128/jb.187.23.8196-8200.2005.

Full text

Abstract:

ABSTRACT Bacterial histidine kinases have been proposed as targets for the discovery of new antibiotics, yet few specific inhibitors of bacterial histidine kinases have been reported. We report here a novel thienopyridine (TEP) compound that inhibits bacterial histidine kinases competitively with respect to ATP but does not comparably inhibit mammalian serine/threonine kinases. Although it partitions into membranes and does not inhibit the growth of bacterial or mammalian cells, TEP could serve as a starting compound for a new class of histidine kinase inhibitors with antibacterial activity.

APA, Harvard, Vancouver, ISO, and other styles

48

Frandsen, Kristian E. H., and Leila Lo Leggio. "Lytic polysaccharide monooxygenases: a crystallographer's view on a new class of biomass-degrading enzymes." IUCrJ 3, no. 6 (October 14, 2016): 448–67. http://dx.doi.org/10.1107/s2052252516014147.

Full text

Abstract:

Lytic polysaccharide monooxygenases (LPMOs) are a new class of microbial copper enzymes involved in the degradation of recalcitrant polysaccharides. They have only been discovered and characterized in the last 5–10 years and have stimulated strong interest both in biotechnology and in bioinorganic chemistry. In biotechnology, the hope is that these enzymes will finally help to make enzymatic biomass conversion, especially of lignocellulosic plant waste, economically attractive. Here, the role of LPMOs is likely to be in attacking bonds that are not accessible to other enzymes. LPMOs have attracted enormous interest since their discovery. The emphasis in this review is on the past and present contribution of crystallographic studies as a guide to functional understanding, with a final look towards the future.

APA, Harvard, Vancouver, ISO, and other styles

49

Conde-Frieboes, Kilian, Michael Ankersen, Jens Breinholt, Birgit Sehested Hansen, Kirsten Raun, Henning Thøgersen, and Birgitte S. Wulff. "Serendipitous discovery of a new class of agonists for the melanocortin 1 and 4 receptors and a new class of cyclophanes." Bioorganic & Medicinal Chemistry Letters 21, no. 5 (March 2011): 1459–63. http://dx.doi.org/10.1016/j.bmcl.2011.01.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Cecchetti, Violetta, Sergio Clementi, Gabriele Cruciani, Arnaldo Fravolini, Pier Giuseppe Pagella, Angela Savino, and Oriana Tabarrini. "6-Aminoquinolones: A New Class of Quinolone Antibacterials?" Journal of Medicinal Chemistry 38, no. 6 (March 1995): 973–82. http://dx.doi.org/10.1021/jm00006a017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!